We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Enhanced S100B Expression in Lymphocytes in Spontaneous Preterm Birth and Preeclampsia

By LabMedica International staff writers
Posted on 16 Nov 2021
Print article
Image: Scanning electron micrograph of a CD4+ T cell – these cells expresses elevated levels of S100B in PE/HELLP patients (Photo courtesy the British Society of Immunology)
Image: Scanning electron micrograph of a CD4+ T cell – these cells expresses elevated levels of S100B in PE/HELLP patients (Photo courtesy the British Society of Immunology)
Preterm birth is commonly defined as any birth before 37 weeks completed weeks of gestation. An estimated 15 million infants are born preterm globally, disproportionately affecting low and middle income countries.

S100B is a calcium-binding peptide and is used as a parameter of glial activation and/or death in many disorders of the central nervous system (CNS). It plays important roles in normal CNS development and recovery after injury. Although S100B is mainly found in astroglial and Schwann cells, it also has extracerebral sources.

A team of Clinical Scientists led by those at the University of Leipzig (Leipzig, Germany) and in collaboration with the Otto von Guericke University (Magdeburg, Germany) determined the concentration of S100B in maternal and cord blood (CB) plasma and placenta supernatant as well as the expression of S100B in maternal and CB CD4+ T cells and CD19+ B cells in Spontaneous Preterm Birth (sPTB) and patients delivering following preeclampsia (PE) and HELLP (hemolysis, elevated liver enzymes, and low platelet count). (PE/HELLP) diagnosis was compared to women delivering at term (TD). The S100B expression was further related to the birth weight in the study cohort.

The investigators reported that S100B concentration was enhanced in maternal and CB plasma of sPTB and PE/HELLP patients and positively correlated with interleukin-6 (IL-6) levels. Increased S100B was also confirmed in CB of small-for-gestational-age (SGA) infants. S100B expression in maternal blood was elevated in CD4+ T cells of PE/HELLP patients and patients who gave birth to SGA newborns as well as in CD19+ B cells of sPTB and PE/HELLP patients and patients with SGA babies. In CB, the expression of S100B was increased in CD19+ B cells of sPTB, PE/HELLP and SGA babies.

The authors concluded that their results support the hypothesis that S100B expression is enhanced in inflammatory events associated with preterm birth and that S100B expression in immune cells is a relevant marker for inflammation during pregnancy complications. The study was published on November 1, 2021 in the Journal of Perinatal Medicine.

Related Links:
University of Leipzig
Otto von Guericke University

Automated ELISA-IFA-BLOT Processor AP 22
Gold Supplier
Pipette Tips
Sapphire Pipette Tips
Electrophoresis Automated System
Auto Scanion
Automatic Specific Protein Analyzer
PA 900

Print article


Molecular Diagnostics

view channel
Image: A new method reliably detects protein changes in blood that are typical of Parkinson`s disease (Photo courtesy of Pexels)

First-Ever Blood Test Detects Parkinson’s Disease

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. However, the disease starts up to 20 years... Read more


view channel
Image: Fujirebio has acquired ADx NeuroSciences for 40 million Euros (Photo courtesy of Pexels)

Fujirebio Acquires ADx NeuroSciences to Speed Development of Neurodegenerative Diseases Diagnostic Tests

Fujirebio Holdings, Inc. (Tokyo, Japan) has announced the acquisition of ADx NeuroSciences (Gent, Belgium) for EUR 40 million in a deal that is expected to close in July 2022, pending the satisfaction... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.